Please assess the completion status of the following clinical trial:

Trial Title: Allogenic Stem Cells Derived From Lipoaspirates for the Treatment of Recto-vaginal Fistulas Associated to Crohn's Disease (ALOREVA)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* Patients with Crohn´s disease diagnosed at least 12 months earlier in accordance with accepted clinical, endoscopic, anatomopathological and/or radiologic criteria.~* Fulfilling one of the following criteria:~  * At least, one previous surgery for fistulous disease.~ * Physical status which discourage liposuction.~* Rectovaginal fistula.~* Women of a childbearing age. Good general state of health according to the findings of the clinical history and the physical examination.~Exclusion Criteria:~* Presence of severe proctitis (prominent friability, spontaneous bleeding, multiple erosions, deep ulcers) or dominant active luminal disease requiring immediate therapy, assessed by rectosigmoidoscopy~* Patients with CDAI≥201~* Patients with an abscess unless a complete toilet of the area with drainage of the collections and the absence of abscess and other collections is confirmed prior to treatment start~* Patients who have received infliximab or any other anti TNF agent in the 8 weeks before the cell treatment administration~* Patients who have received tacrolimus or cyclosporine in the 4 weeks before the cell treatment administration~* Patients with a history of abuse of alcohol or other addictive substances in the 6 months prior to inclusion~* Patients with malignant tumor, except for basal cell or cutaneous squamous cell carcinoma, or patients with a prior history of malignant tumors, unless the neoplastic disease has been in remission for the previous 5 years~* Patients with cardiopulmonary disease which, in opinion of the investigator, in unstable or sufficiently serious to exclude the patient from the study.~* Patients with any type of medical or psychiatric disease which, in the opinion of the investigator, could be grounds for exclusion from study~* Patients with congenital or acquired immunodeficiencies. HIV, HBV, HCV or treponema infection, whether active or latent.~* Patients allergic to local anesthetics or gadolinium (MRI contrast) MRI is unfeasible (e.g. due to the presence of pacemakers, hip replacements or severe claustrophobia)~* Patients who have suffering major surgery or severe trauma in the prior 6 months~* Pregnant or breastfeeding women~* Patients currently receiving, or having received within 1 month prior to enrolment into this clinical trial, any investigational drug.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Allogenic ASCs (Type: EXPERIMENTAL): Intralesional dose of 20 million cells at baseline with a possible second administration of 40 million in case of incomplete fistula closure following week 12 assessment.

Based on this trial design, predict the completion outcome and termination type (if applicable).